AMA Struggles to Reign in Consumer Drug Ads
You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?
Pharmaguy™’s Twitter Stream – Q4 2009
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Peter Kirk: Sermo vs. Doximity = “Facebook” vs. “LinkedIn” for Docs
In this 3-minute audio snippet, Peter Kirk, CEO, Sermo, talks about the differences between Doximity and Sermo with regard to online physician discussions and the benefits of anonymity.
Profile of Pharmaguy™’s Twitter Followers
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy’s Social Media Timeline
Pharmaguy's Social Media Timeline
Tom Stossel: Debunking the “Conflict-of-Interest Narrative”
In this 5-minute audio snippet, Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, talks about what he calls the 'Conflict-of-Interest Narrative' or Myth, which is the subject of his new book, PharmaPhobia.
Pharmaguy™
Pharmaguy™ is a Pharma Marketing 'Constructive' Critic, Blogger & Chief Pundit at Pharmaguy.com
Pharmaguy™’s Twitter Stream – Q2 2010
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Ambre Morley: Vetting Celebrity Spokespersons to Ensure Return on Investment
In this 2-minute audio snippet, Ambre Morley, Associate Director, Product Communications, Novo Nordisk, talks about vetting Paula Deen as a paid celebrity spokesperson for the Novo Victoza diabetes drug franchise and the importance of measuring celebrity return on investment (ROI).
Roland Andersson & Thomas Krohn: Transcelerate BioPharma Initiative
In this 4-minute audio snippet, Roland Andersson, Director for Accenture's Life Sciences R&D practice, and Thomas Krohn, Director, Clinical Open Innovation, Eli Lilly, discuss the Transcelerate Biopharma initiative, the goals of which are to increase compliance and the productivity of clinical trials.
